Literature DB >> 18589230

Transfemoral endovascular treatment of proximal common carotid artery lesions: a single-center experience on 153 lesions.

Tamás Mirkó Paukovits1, Judit Haász, Andrea Molnár, Zoltán Szeberin, Balázs Nemes, Dániel Varga, Kálmán Hüttl, Viktor Bérczi, Gergely Léránt.   

Abstract

PURPOSE: To assess primary success and safety of percutaneous transluminal angioplasty (PTA) and/or stenting of ostial/proximal common carotid artery lesions (pCCA) and to compare its 30-day stroke/mortality level with the literature data for surgical options.
METHODS: A total of 147 patients (153 stenoses, 6 recurrent) (71 female; 121 left) with significant diameter stenosis (>70% in symptomatic, n = 46; >85% in asymptomatic, n = 101 patients) of pCCA treated between 1994 and 2006 were retrospectively reviewed. With the exception of one, all procedures were performed using a transfemoral approach. A stent was implanted in 108 (70.5%) of cases. Stents were not available in the early years of our experience, but gradually became a routine practice. Embolic protection devices were used in 16 cases. Follow-up included neurological examination, carotid duplex scan, and office/telephone interview.
RESULTS: Primary technical success was 98.7% (151/153 stenoses). There were no deaths. Periprocedural (<48 hours) neurological complications included 3/153 (2.0%) ipsilateral major strokes and 4/153 (2.6%) TIAs (including one contralateral TIA). There were 8/153 (5.2%) access site hematomas, 1/153 (0.7%) bradycardia, and 1/153 (0.7%) acute left ventricular failure with respiratory distress. Follow-up was achieved in 115/147 patients (78.2%) undergoing 120 procedures for a mean of 24.7 months and revealed one additional contralateral TIA and one additional minor stroke in an asymptomatic patient. In patients with follow-up, the 30-day procedural death/all-stroke rate was 3/120 (2.5%) The cumulative primary patency rate in the 115 patients with follow-up was 97.9% +/- 2.1% at 1 year, 82.0% +/- 7.1% at 4-years, and 73.5% +/- 12.7% at 7 years. The cumulative secondary patency rate was 100% at 1 year, 88.0% +/- 7.0% at 4 years, and 88.0% +/- 11% at 7 years. Log-rank test showed no statistical difference (P = .82) in primary cumulative patency between PTA alone (n = 34) or PTA/stent (n = 86).
CONCLUSION: Transfemoral PTA/stenting appears to be appropriate treatment option for ostial/proximal common carotid artery significant stenoses. This study should also draw attention to the lack of data on natural history or effect of best medical treatment alone for these lesions, making evidence-based decision currently impossible for treatment of symptomatic or asymptomatic ostial and proximal common carotid artery significant stenoses.

Entities:  

Mesh:

Year:  2008        PMID: 18589230     DOI: 10.1016/j.jvs.2008.03.008

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Impact of Adding Carotid Endarterectomy to Supra-aortic Trunk Surgical Reconstruction.

Authors:  Linda J Wang; Sarah C Crofts; Thomas P Nixon; Bernadette J Goudreau; David C Chang; Mark F Conrad; Matthew J Eagleton; W Darrin Clouse
Journal:  Ann Vasc Surg       Date:  2020-06-26       Impact factor: 1.466

2.  A case of tandem stenoses at the proximal common and internal carotid arteries treated with transbrachial stenting: a case report.

Authors:  Hidemichi Ito; Masashi Uchida; Taigen Sase; Yuichiro Kushiro; Tetsuya Ikeda; Hiroshi Takasuna; Ichiro Takumi; Kotaro Oshio; Yuichiro Tanaka
Journal:  Interv Neuroradiol       Date:  2018-11-04       Impact factor: 1.610

3.  Rendezvous endovascular common carotid artery stenting (RECCAS) technique for symptomatic steno-occlusive disease.

Authors:  M T Wang; M Schembri; H K Kok; J Maingard; M Foo; A Lamanna; M Brooks; H Asadi
Journal:  CVIR Endovasc       Date:  2021-01-18

Review 4.  Clinical Outcomes of Second- versus First-Generation Carotid Stents: A Systematic Review and Meta-Analysis.

Authors:  Adam Mazurek; Krzysztof Malinowski; Kenneth Rosenfield; Laura Capoccia; Francesco Speziale; Gianmarco de Donato; Carlo Setacci; Christian Wissgott; Pasqualino Sirignano; Lukasz Tekieli; Andrey Karpenko; Waclaw Kuczmik; Eugenio Stabile; David Christopher Metzger; Max Amor; Adnan H Siddiqui; Antonio Micari; Piotr Pieniążek; Alberto Cremonesi; Joachim Schofer; Andrej Schmidt; Piotr Musialek
Journal:  J Clin Med       Date:  2022-08-17       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.